Tisagenlecleucel Is Safe and Effective in Relapsed/Refractory Follicular Lymphoma

被引：0
|
作者：
Fowler, N. H.
Dickinson, M.
Dreyling, M.
Martinez-Lopez, J.
Kolstad, A.
Butler, J.
机构：
来源：
CANCER DISCOVERY | 2022年 / 12卷 / 03期
关键词：
D O I：
10.1158/2159-8290.CD-RW2022-004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tisagenlecleucel is safe and effective for adults with pretreated relapsed/refractory follicular lymphoma (FL). ©2022 American Association for Cancer Research.
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 ELARA Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [22] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
    Fukuhara, Noriko
    Kato, Koji
    Goto, Hideki
    Takeshi, Tajima
    Kawaguchi, Mayu
    Tokushige, Kota
    Akashi, Koichi
    Teshima, Takanori
    Harigae, Hideo
    Schuster, Stephen J.
    Thieblemont, Catherine
    Dreyling, Martin
    Fowler, Nathan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 251 - 259
  • [23] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
    Noriko Fukuhara
    Koji Kato
    Hideki Goto
    Tajima Takeshi
    Mayu Kawaguchi
    Kota Tokushige
    Koichi Akashi
    Takanori Teshima
    Hideo Harigae
    Stephen J. Schuster
    Catherine Thieblemont
    Martin Dreyling
    Nathan Fowler
    International Journal of Hematology, 2023, 117 : 251 - 259
  • [24] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 45 - 56
  • [25] Emerging therapies for the treatment of relapsed or refractory follicular lymphoma
    MacDonald, D.
    Prica, A.
    Assouline, S.
    Christofides, A.
    Lawrence, T.
    Sehn, L. H.
    CURRENT ONCOLOGY, 2016, 23 (06) : 407 - 417
  • [26] How I Treat Relapsed/Refractory Follicular Lymphoma
    Martin, Peter
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 2 - 5
  • [27] Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma
    Mondello, Patrizia
    Ansell, Stephen M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (03) : 295 - 301
  • [28] Treatment selection for patients with relapsed or refractory follicular lymphoma
    Skarbnik, Alan Z.
    Patel, Krish
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Treatment Selection in Patients With Relapsed or Refractory Follicular Lymphoma
    Pagel, John M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (12) : 11 - 14
  • [30] Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma
    Cohen, Jared A.
    Ghobadi, Armin
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (09) : 903 - 914
12345